Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1903144 | 1.00 | PLA2G4A (0.59) | PLA2G4AMAPTMEN1LMNAKMT2A | |
| SCHEMBL15709537 | 1.00 | PLA2G4A (0.59) | PLA2G4AMAPTMEN1LMNAKMT2A | |
| SCHEMBL31697463 | 1.00 | PLA2G4A (0.59) | PLA2G4AMAPTMEN1LMNAKMT2A | |
| SCHEMBL11249530 | 0.88 | PLA2G4A (0.52) | PLA2G4AMAPTMEN1LMNAKMT2A | |
| SCHEMBL3608478 | 0.88 | PLA2G4A (0.52) | PLA2G4AMAPTMEN1LMNAKMT2A | |
| SCHEMBL3608483 | 0.88 | PLA2G4A (0.52) | PLA2G4AMAPTMEN1LMNAKMT2A | |
| SCHEMBL2785445 | 0.83 | ALDH5A1 (0.63) | PLA2G4AMAPTMEN1LMNAKMT2A | |
| SCHEMBL10780080 | 0.83 | MAPT (0.64) | PLA2G4AMAPTMEN1LMNAKMT2A | |
| SCHEMBL7166946 | 0.83 | ALDH5A1 (0.63) | PLA2G4AMAPTMEN1LMNAKMT2A | |
| SCHEMBL2785447 | 0.83 | ALDH5A1 (0.63) | PLA2G4AMAPTMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3889138-B1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024149093-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-07-18 | — | — | WO | disclosed |
| EP-3816158-B1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS | KPC PHARMACEUTICALS INC (CN) | 2023-10-25 | — | — | EP | disclosed |
| CN-112533903-B | Benzimidazole derivatives and their use as IDH1 inhibitors | 昆药集团股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11407717-B2 | Benzimidazole derivatives and use thereof as IDH1 inhibitors | KPC PHARMACEUTICALS, INC. (CN) | 2022-08-09 | — | — | US | disclosed |
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| EP-3889138-A1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2021-10-06 | — | — | EP | disclosed |
| US-20210206728-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS | KPC PHARMACEUTICALS, INC. (CN) | 2021-07-08 | — | — | US | disclosed |
| EP-3816158-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS | KPC Pharmaceuticals, Inc. (CN) | 2021-05-05 | — | — | EP | disclosed |
| CN-112533903-A | Benzimidazole derivatives and their use as IDH1 inhibitors | 昆药集团股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-9309198-B2 | N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | US | disclosed |
| US-9018414-B2 | Substituted 3-phenylpropionic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| EP-2493845-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051165-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | GUCY1A2, GUCY1A1, GUCY1B2 | PLA2G4A 122/4885MAPT 4762/4885MEN1 4072/4885 |
| US-11407717-B2 | Benzimidazole derivatives and use thereof as IDH1 inhibitors | IDH1, IDH3A, IDH2 | PLA2G4A 4841/4885MAPT 90/4885MEN1 273/4885 |
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | PLA2G4A 936/4885MAPT 3095/4885MEN1 4182/4885 |
| US-20210206728-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS | IDH1, IDH3A, IDH2 | PLA2G4A 4841/4885MAPT 90/4885MEN1 273/4885 |
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | EP300, HDAC1, HDAC11 | PLA2G4A 3796/4885MAPT 2313/4885MEN1 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.